trial · primary record
Capecitabine
Estrogen Receptor Negative
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 415 |
| Primary completion | 2031-03-29 |
| Primary endpoint | 3-year Invasive Disease-Free Survival (IDFS) Rate in Basal-Subtype Patients |
| Registry ID | NCT02445391 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:51.931Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02445391
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Capecitabine · approval
- Capecitabine · compound